2015 Annual Meeting of the American Association for the Study of Liver Diseases*

November 13-17, 2015; San Francisco, California
CCO’s Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases includes Capsule Summaries, reviews by expert faculty on key studies highlighted at the conference and a downloadable slide set.

Clinical Impact of New Data From AASLD 2015


One-pill, once-daily combination superior to sofosbuvir plus ribavirin, with no cases of virologic failure in open-label phase III trial.

Released: November 19, 2015

Use of shorter 12-week treatment regimen highly effective in patients with F3 disease.

Released: November 17, 2015

Similar SVR24 rates in white patients vs black patients; SVR12 rate not affected by baseline RAVs in patients with genotype 1a HCV infection.

Released: November 20, 2015

Low rates of discontinuation due to AEs, treatment-related serious AEs, and/or grade 3 and 4 lab abnormalities in this interim analysis.

Released: November 20, 2015

Analysis finds 8-week regimen is underused, despite being highly effective in qualifying patients.

Released: November 17, 2015

High SVR rates maintained across patient subgroups, including cirrhotic and treatment-experienced patients; adverse event rates similar to placebo.

Released: November 18, 2015

Both 12-week and 16-week regimens of daclatasvir plus sofosbuvir plus ribavirin were well tolerated, even in cirrhotic, treatment-experienced patients usually considered difficult to treat.

Released: November 20, 2015

No relapse in noncirrhotic patients regardless of inclusion of ribavirin; no relapse in cirrhotic patients with 16 weeks of treatment including ribavirin.

Released: November 19, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?